Skip to main content
ACRS
NASDAQ Life Sciences

FDA Fast Tracks Aclaris' Modzatinib for Lichen Planus, Phase 2b Trial Set for Q4

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$6.338
Mkt Cap
$850.552M
52W Low
$1.52
52W High
$6.515
52W Position info
317% above low
Off High info
2.7% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

ACRS has more than doubled off its 52-week low of $1.52.

Summary

The FDA granted Fast Track designation to modzatinib (ATI-2138) for moderate to severe lichen planus, a disease with no approved therapies. This regulatory milestone enables more frequent FDA interactions, rolling NDA review, and potential Priority Review eligibility. Aclaris plans to start a phased Phase 2b trial in Q4 2026, moving the program toward registration. The company recently reported $170.6M in cash plus $40.2M raised post-quarter, providing runway to advance this and other pipeline assets. With the stock near its 52-week high, the designation validates the program's potential in an underserved market.

At the time of this announcement, ACRS was trading at $6.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $850.6M. The 52-week trading range was $1.52 to $6.52. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ACRS - Latest Insights

ACRS
Nov 16, 2026, 6:03 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.28
Real-time Price: $3.46 info
Change: +$0.175 (+5%) info
Market Cap: $549.591M info
ACRS
Nov 16, 2026, 3:28 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.76
Real-time Price: $3.46 info
Change: -$0.305 (-8%) info
Market Cap: $549.591M info
ACRS
Nov 05, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.46 info
Change: -$0.155 (-4%) info
Market Cap: $549.591M info
ACRS
Nov 05, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.46 info
Change: -$0.155 (-4%) info
Market Cap: $549.591M info
ACRS
Oct 27, 2026, 5:15 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.72
Real-time Price: $3.46 info
Change: -$0.265 (-7%) info
Market Cap: $549.591M info